Bachem Holding AG
SIX:BANB

Watchlist Manager
Bachem Holding AG Logo
Bachem Holding AG
SIX:BANB
Watchlist
Price: 67.5 CHF -3.3% Market Closed
Market Cap: 5.1B CHF
Have any thoughts about
Bachem Holding AG?
Write Note

Bachem Holding AG
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bachem Holding AG
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Bachem Holding AG
SIX:BANB
Cash from Operating Activities
CHf243.5m
CAGR 3-Years
28%
CAGR 5-Years
34%
CAGR 10-Years
19%
Siegfried Holding AG
SIX:SFZN
Cash from Operating Activities
CHf248.8m
CAGR 3-Years
14%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Lonza Group AG
SIX:LONN
Cash from Operating Activities
CHf1.5B
CAGR 3-Years
7%
CAGR 5-Years
13%
CAGR 10-Years
10%
Tecan Group AG
SIX:TECN
Cash from Operating Activities
CHf121.5m
CAGR 3-Years
-20%
CAGR 5-Years
6%
CAGR 10-Years
N/A
PolyPeptide Group AG
SIX:PPGN
Cash from Operating Activities
€36.5m
CAGR 3-Years
-10%
CAGR 5-Years
10%
CAGR 10-Years
N/A
SKAN Group AG
SIX:SKAN
Cash from Operating Activities
CHf8.7m
CAGR 3-Years
-27%
CAGR 5-Years
31%
CAGR 10-Years
N/A
No Stocks Found

Bachem Holding AG
Glance View

Market Cap
5.1B CHF
Industry
Life Sciences Tools & Services

Bachem Holding AG engages in the provision of peptides and oligonucleotides. The company is headquartered in Bubendorf, Basel-Landschaft and currently employs 1,639 full-time employees. The company went IPO on 2001-06-29. The firm focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The firm markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.

BANB Intrinsic Value
90.95 CHF
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Bachem Holding AG's Cash from Operating Activities?
Cash from Operating Activities
243.5m CHF

Based on the financial report for Jun 30, 2024, Bachem Holding AG's Cash from Operating Activities amounts to 243.5m CHF.

What is Bachem Holding AG's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
19%

Over the last year, the Cash from Operating Activities growth was 78%. The average annual Cash from Operating Activities growth rates for Bachem Holding AG have been 28% over the past three years , 34% over the past five years , and 19% over the past ten years .

Back to Top